EUTM file information

018651177

VOYAGER


February 8, 2022

Trademark Summary

The trademark application VOYAGER was filed by Voyager Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on May 16, 2022, and it was registered by office on August 23, 2022 without any oppositions.

The application was filed in English (German was selected as the second language).


Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Biological preparations for gene therapy
    2. Adeno-associated virus (AAV) gene therapy
    3. Biological preparations for treatment of neurological diseases and disorders
    4. Gene therapy preparations for treatment of disease, namely, treatment of disease, namely, neurological diseases
    5. Treatments for neurological diseases via gene replacement, gene knockdown, or vectorized antibodies
    6. Gene therapy preparations for neurological diseases
    7. Polypeptides for gene therapy
    8. Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics
    9. Drug delivery agents consisting of capsids that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics.
  • The mark was filed in class 42 with following description of goods:
    1. Pharmaceutical research and development in the field of gene therapy
    2. Pharmaceutical research and development for the treatment of neurological diseases and disorders
    3. Scientific research in the field of gene therapy
    4. Pharmaceutical research services
    5. Research and development of pharmaceutical preparations for gene therapy
    6. Research and development of pharmaceutical preparations for neurological diseases
    7. Biotechnology research services
    8. Research and development of platform technologies for genetic delivery of therapies and pharmaceuticals
    9. Research, development, and collaboration services in the field of platforms technologies for genetic delivery of therapies and pharmaceuticals
    10. Research and development in the pharmaceutical and biotechnology fields
    11. Research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic deliver of therapies and pharmaceuticals
    12. Research and development regarding the identification and targeting of specific cells and tissues for gene therapy delivery
    13. Providing scientific research information in the field of clinical trials and gene therapy
    14. Providing medical research.
  • The mark was filed in class 44 with following description of goods:
    1. Medical services provided for clinical trials
    2. Providing patient care for clinical trials
    3. Providing medical information in the field of clinical trials and gene therapy
    4. Providing medical information through a website.